好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Improvement in Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification
Headache
P1 - Poster Session 1 (5:30 PM-6:30 PM)
13-013
To evaluate responder rates using different response thresholds as a measure of efficacy of fremanezumab in adults with chronic migraine (CM) who reverted to episodic migraine (EM).
CM is a distinct disorder with a clinical profile and response pattern from that of EM. Fremanezumab, a fully humanized monoclonal antibody (IgG2Δa) that selectively targets calcitonin gene-related peptide (CGRP), is approved in the US for the preventive treatment of migraine. A proportion of fremanezumab-treated patients experienced reversion from CM to EM.

In this 52-week, multicenter, randomized, double-blind, parallel-group study, patients with CM received either subcutaneous fremanezumab monthly (225 mg every month; starting dose of 675 mg) or quarterly (675 mg every 3 months). This post hoc analysis evaluated the proportions of patients achieving ≥50%, ≥75%, or 100% reduction in the monthly average number of headache days of at least moderate severity or migraine days in patients with CM who reverted to an EM classification, defined as having ≥15 headache days at baseline and <15 headache days at Month 12.
Of 813 patients with CM at baseline, 548 reverted from CM to EM. Among those patients, at Month 6, 66.9%, 38.4%, and 14.4% of patients in the quarterly group; and 72.8%, 42.0%, and 15.5% in the monthly group achieved ≥50%, ≥75%, and 100% reduction in the monthly average number of headache days of at least moderate severity, respectively. At Month 12, the response rates further increased to 75.7%, 45.6%, and 21.7% in the quarterly group; and 77.7%, 49.5%, and 18.0% in the monthly group, respectively. A similar pattern was observed for migraine-day responder rates.
In fremanezumab-treated patients who reverted from CM to EM, clinically relevant response rates were sustained over the long term, and greater improvements were observed with longer time on treatment.
Authors/Disclosures
Rashmi B. Halker Singh, MD, FAAN (Mayo Clinic)
PRESENTER 		Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Halker Singh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Current Neurology & Neuroscience Reports. Dr. Halker Singh has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache Journal. Dr. Halker Singh has received publishing royalties from a publication relating to health care. Dr. Halker Singh has received personal compensation in the range of $5,000-$9,999 for serving as a CME speaker with Pri-med. Dr. Halker Singh has received personal compensation in the range of $500-$4,999 for serving as a CME speaker with Medscape.
Michael J. Marmura, MD, FAAN (Thomas Jefferson University) Dr. Marmura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Marmura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. The institution of Dr. Marmura has received research support from Teva. The institution of Dr. Marmura has received research support from AbbVie. The institution of Dr. Marmura has received research support from Axsome. The institution of Dr. Marmura has received research support from Pfizer. Dr. Marmura has received publishing royalties from a publication relating to health care. Dr. Marmura has received publishing royalties from a publication relating to health care. Dr. Marmura has received publishing royalties from a publication relating to health care.
Joshua M. Cohen, MD No disclosure on file
Paul P. Yeung, MD, PhD No disclosure on file
No disclosure on file